Trial Profile
A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Apr 2024
Price :
$35
*
At a glance
- Drugs Balstilimab (Primary) ; Botensilimab (Primary)
- Indications Cervical cancer; Colorectal cancer; Endometrial cancer; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Agenus
- 24 Apr 2024 According to an Agenus media release, data from the study will be presented at the upcoming American Society of Clinical Oncology (ASCO) Meeting, to be held May 31 June 4, 2024, in Chicago, IL for a sub-analysis of the r/r MSS CRC cohort of the Phase 1b study.
- 12 Apr 2024 According to an Agenus media release, Pending planned meetings with the FDA, Agenus plans to submit a Biologics License Application (BLA) for BOT/BAL in refractory MSS CRC later this year and plans to present Phase 1 survival data, at a major medical conference in the second half of 2024.
- 12 Apr 2024 Results (at the data cutoff of March 1, 2024, n=77) presented in the Agenus Media Release.